Guardion Health Sciences (GHSI) 10-Q12 Nov 202020 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 12, 2020
Cover [Abstract]
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	0001642375
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		88,327,312
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash	$ 9,795,441	$ 11,115,502
Accounts receivable	22,849	78,337
Inventories, net	1,284,173	310,941
Prepaid expenses	231,621	362,938
Total current assets	11,334,084	11,867,718
Deposits	11,751	11,751
Property and equipment, net	305,600	374,638
Right-of-use asset, net	457,677	572,714
Intangible assets	50,000	50,000
Total assets	12,159,112	12,876,821
Current liabilities
Accounts payable	576,890	70,291
Accrued expenses	182,597	175,052
Due to former officer	230,208
Derivative warrant liability	7,519	13,323
Lease liability - current	159,962	151,568
Total current liabilities	1,157,176	410,234
Lease liability - long term	313,909	434,747
Total liabilities	1,471,085	844,981
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value; 250,000,000 shares authorized; 88,327,312 and 74,982,562 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	88,327	74,983
Additional paid-in capital	61,308,938	57,468,528
Accumulated deficit	(50,709,238)	(45,511,671)
Total stockholders' equity	10,688,027	12,031,840
Total liabilities and stockholders' equity	$ 12,159,112	$ 12,876,821

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	88,327,312	74,982,562
Common stock, shares outstanding	88,327,312	74,982,562

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue
Total revenue	$ 253,188	$ 161,162	$ 1,689,820	$ 664,669
Cost of goods sold
Total cost of goods sold	114,113	70,999	867,800	261,547
Gross profit	139,075	90,163	822,020	403,122
Operating expenses
Research and development	34,034	31,897	109,803	138,613
Sales and marketing	167,213	448,387	1,175,126	1,246,846
General and administrative	2,070,998	2,022,367	5,299,696	5,427,573
Costs related to resignation of former officer (including the reversal of previously recognized stock compensation expense of $965,295 during the nine months ended September 30, 2020)			(615,936)
Loss on sale of equipment	18,500		18,500
Impairment loss on equipment			30,948
Total operating expenses	2,290,745	2,502,651	6,018,137	6,813,032
Loss from operations	(2,151,670)	(2,412,488)	(5,196,117)	(6,409,910)
Other (income) expense:
Interest expense	3,716	4,205	7,254	255,842
Finance cost upon issuance of warrants				415,955
Change in fair value of derivative warrants	(11,892)	(31,322)	(5,804)	(259,154)
Total other (income) expense	8,176	(27,117)	1,450	412,643
Net loss	$ (2,143,494)	$ (2,385,371)	$ (5,197,567)	$ (6,822,553)
Net loss per common share - basic and diluted	$ (0.02)	$ (0.07)	$ (0.06)	$ (0.26)
Weighted average common shares outstanding - basic and diluted	88,320,523	36,035,309	84,530,367	26,483,713
Medical Foods and Nutraceuticals [Member]
Revenue
Total revenue	$ 142,556	$ 112,957	$ 1,446,584	$ 317,338
Cost of goods sold
Total cost of goods sold	68,956	41,655	764,245	120,608
Medical Devices [Member]
Revenue
Total revenue	110,632	44,705	237,136	337,531
Cost of goods sold
Total cost of goods sold	45,157	27,922	101,077	136,958
Other [Member]
Revenue
Total revenue		3,500	6,100	9,800
Cost of goods sold
Total cost of goods sold		$ 1,422	$ 2,478	$ 3,981

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical)	9 Months Ended
	Sep. 30, 2020USD ($)
Income Statement [Abstract]
Recognized stock compensation expense	$ (965,295)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 20,564	$ 37,798,562	$ (34,633,363)	$ 3,185,763
Balance, shares at Dec. 31, 2018	20,564,328
Fair value of vested stock options		56,232		56,232
Issuance of common stock - warrant exercises	$ 293	30,957		31,250
Issuance of common stock - warrant exercises, shares	292,283
Net loss			(1,385,099)	(1,385,099)
Balance at Mar. 31, 2019	$ 20,857	37,885,751	(36,018,462)	1,888,146
Balance, shares at Mar. 31, 2019	20,856,611
Balance at Dec. 31, 2018	$ 20,564	37,798,562	(34,633,363)	3,185,763
Balance, shares at Dec. 31, 2018	20,564,328
Issuance of common stock - conversion of notes payable and related interest				250,788
Net loss				(6,822,553)
Balance at Sep. 30, 2019	$ 50,483	49,454,265	(41,455,916)	8,048,832
Balance, shares at Sep. 30, 2019	50,482,562
Balance at Dec. 31, 2018	$ 20,564	37,798,562	(34,633,363)	3,185,763
Balance, shares at Dec. 31, 2018	20,564,328
Fair value of warrants				13,323
Balance at Dec. 31, 2019	$ 74,983	57,468,528	(45,511,671)	12,031,840
Balance, shares at Dec. 31, 2019	74,982,562
Balance at Mar. 31, 2019	$ 20,857	37,885,751	(36,018,462)	1,888,146
Balance, shares at Mar. 31, 2019	20,856,611
Fair value of vested stock options - officer and director		1,066,159		1,066,159
Fair value of vested stock options		62,763		62,763
Issuance of common stock for services	$ 55	123,947		124,002
Issuance of common stock for services, shares	54,387
Issuance of common stock - warrant exercises	$ 463	100,162		100,625
Issuance of common stock - warrant exercises, shares	463,726
Fair value of warrants		359,683		359,683
Sale of common stock	$ 1,250	3,886,750		3,888,000
Sale of common stock, shares	1,250,000
Issuance of common stock - conversion of notes payable and related interest	$ 109	250,679		250,788
Issuance of common stock - conversion of notes payable and related interest, shares	109,038
Net loss			(3,052,078)	(3,052,078)
Balance at Jun. 30, 2019	$ 22,734	43,735,894	(39,070,540)	4,688,088
Balance, shares at Jun. 30, 2019	22,733,762
Fair value of vested stock options - officer and director		722,592		722,592
Fair value of vested stock options		56,688		56,688
Issuance of common stock - warrant exercises	$ 15,749	6,751		22,500
Issuance of common stock - warrant exercises, shares	15,748,800
Fair value of warrants
Sale of common stock	$ 12,000	4,932,340		4,944,340
Sale of common stock, shares	12,000,000
Net loss			(2,385,376)	(2,385,371)
Balance at Sep. 30, 2019	$ 50,483	49,454,265	(41,455,916)	8,048,832
Balance, shares at Sep. 30, 2019	50,482,562
Balance at Dec. 31, 2019	$ 74,983	57,468,528	(45,511,671)	12,031,840
Balance, shares at Dec. 31, 2019	74,982,562
Fair value of vested stock options - officer and director		436,287		436,287
Fair value of vested stock options		55,281		55,281
Issuance of common stock for services	$ 25	12,300		12,325
Issuance of common stock for services, shares	25,000
Issuance of common stock - warrant exercises	$ 10,382	3,540,399		3,550,781
Issuance of common stock - warrant exercises, shares	10,382,400
Net loss			(2,346,913)	(2,346,913)
Balance at Mar. 31, 2020	$ 85,390	61,512,795	(47,858,584)	13,739,601
Balance, shares at Mar. 31, 2020	85,389,962
Balance at Dec. 31, 2019	$ 74,983	57,468,528	(45,511,671)	12,031,840
Balance, shares at Dec. 31, 2019	74,982,562
Issuance of common stock for services, shares	25,000
Fair value of warrants				7,519
Issuance of common stock - conversion of notes payable and related interest
Net loss				(5,197,567)
Balance at Sep. 30, 2020	$ 88,327	61,308,938	(50,709,238)	10,688,027
Balance, shares at Sep. 30, 2020	88,327,312
Balance at Mar. 31, 2020	$ 85,390	61,512,795	(47,858,584)	13,739,601
Balance, shares at Mar. 31, 2020	85,389,962
Fair value of vested stock options - officer and director		(1,377,223)		(1,377,223)
Fair value of vested stock options		41,782		41,782
Issuance of common stock - warrant exercises	$ 2,920	995,720		998,640
Issuance of common stock - warrant exercises, shares	2,920,000
Net loss			(707,160)	(707,160)
Balance at Jun. 30, 2020	$ 88,310	61,173,074	(48,565,744)	12,695,640
Balance, shares at Jun. 30, 2020	88,309,962
Fair value of vested stock options		129,948		129,948
Issuance of common stock - warrant exercises	$ 17	5,916		5,933
Issuance of common stock - warrant exercises, shares	17,350
Net loss			(2,143,494)	(2,143,494)
Balance at Sep. 30, 2020	$ 88,327	$ 61,308,938	$ (50,709,238)	$ 10,688,027
Balance, shares at Sep. 30, 2020	88,327,312

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating Activities
Net loss	$ (5,197,567)	$ (6,822,553)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	45,552	209,813
Impairment loss on equipment	30,948
Loss on sale of equipment	18,500
Amortization of debt discount		250,000
Amortization of right-of-use asset	115,037	93,222
Accrued interest expense included in notes payable		788
Stock-based compensation	239,336	299,684
Stock-based compensation - former officer	(940,936)	1,788,751
Non-cash financing costs - derivative liability		415,955
Change in fair value of warrants - derivative liability	(5,804)	(259,154)
(Increase) decrease in -
Accounts receivable	55,488	(6,275)
Inventories	(656,283)	37,642
Prepaid expenses	(176,861)	(186,611)
Increase (decrease) in -
Accounts payable	506,599	156,314
Lease liability	(112,444)	(86,902)
Accrued expenses	7,545	(49,814)
Due to former officer	230,208
Net cash used in operating activities	(5,840,682)	(4,189,050)
Investing Activities
Proceeds from sale of equipment	6,000
Purchase of property and equipment	(40,733)	(163,105)
Net cash used in investing activities	(34,733)	(163,105)
Financing Activities
Proceeds from initial public offering		3,888,000
Proceeds from follow-on public offering		4,944,340
Proceeds from issuance of convertible notes		250,000
Proceeds from issuance of promissory notes		100,000
Payments on promissory notes		(100,548)
Proceeds from exercise of warrants	4,555,354	154,375
Net cash provided by financing activities	4,555,354	9,236,167
Cash:
Net increase (decrease)	(1,320,061)	4,884,012
Balance at beginning of period	11,115,502	670,948
Balance at end of period	9,795,441	5,554,960
Cash paid for:
Interest	7,254
Income taxes
Non-cash financing activities:
Fair value of warrant liability issued in connection with issuance of convertible notes		436,034
Recording of lease asset and liability upon adoption of ASU 2016-02		663,218
Reclassification of prepaid costs to inventory	308,178
Reclassification of property and equipment to equipment held for sale	55,448
Reclassification of property and equipment to inventory	8,771
Reclassification of warrant liability to equity		359,683
Fair value of common stock issued upon conversion of common stock and accrued interest		250,788
Reclassification of deferred offering cost to equity		$ 270,000

Organization and Business Opera

Organization and Business Operations	9 Months Ended
Organization and Business Operations	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Organization and Business Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. The Company’s wholly-owned subsidiaries consist of VectorVision Ocular Health, Inc., NutriGuard Formulations, Inc., and Transcranial Doppler Solutions, Inc. Guardion Health Sciences, including its wholly-owned subsidiaries, is referred to herein as the “Company”. The Company is a specialty health sciences company that develops clinically supported nutrition, medical foods and medical devices, with a focus in the ocular health marketplace. Going Concern and Liquidity The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $5,197,567 and utilized cash in operating activities of $5,840,682 during the nine months ended September 30, 2020. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The Company’s independent registered public accounting firm has also included explanatory language in their audit report related to the Company’s financial statements for the year ended December 31, 2019, stating there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company will continue to incur significant expenses for commercialization activities related to its medical foods, nutraceuticals, the MapcatSF medical device, VectorVision diagnostic equipment, and with respect to efforts to continue to build the Company’s infrastructure. Development and commercialization of medical foods, nutraceuticals and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new complementary products or product lines. Management is continuing to (i) review its business segments and operations in order to determine its future business strategies and focus, and (ii) explore, with the assistance of a qualified financial advisor, potential transaction opportunities designed to enhances stockholder value. Furthermore, management is reviewing its expense profile in order to increase efficiencies and reduce its cash utilization over the near-term. The Company intends to seek to raise additional debt and/or equity capital to fund future operations and/or acquisitions, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations. COVID-19 The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic has had and will continue to have on the Company’s business is highly uncertain and difficult to predict and quantify, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, economies worldwide have also been negatively impacted by the COVID-19 pandemic. Policymakers around the globe have responded with fiscal policy actions intended to support the healthcare industry and economy as a whole, but it is presently unknown whether and to what extent further fiscal actions will continue or be effective. The magnitude and overall effectiveness of these actions remain uncertain. The severity of the impact of the COVID-19 pandemic on the Company’s business will continue to depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of the Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain. NASDAQ Delisting Notice On September 20, 2019, the Company received a notification letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq letter had no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq listing rules, the Company was provided an initial period of 180 calendar days, or until March 18, 2020, to regain compliance with the Minimum Bid Price Requirement. The Company was unable to regain compliance with the Minimum Bid Price Requirement during the initial period and was eligible for an additional 180 calendar day compliance period under the NASDAQ listing rules. The Company provided written notice of its intention to cure the deficiency during the additional compliance period, and o n March 19, 2020, the Company received a written notification from Nasdaq that the Company had been granted an additional 180 calendar days, or until September 14, 2020, to regain compliance with The current COVID-19 crisis has created unprecedented turmoil in U.S. and world financial markets and has significantly impacted investor confidence. Given these extraordinary market conditions, Nasdaq tolled the compliance periods for bid price and market value of publicly held shares through June 30, 2020 (the “Price-based Requirements”). Accordingly, since the Company had 152 calendar days remaining in its bid price compliance period as of April 16, 2020, it will, upon reinstatement of the Price-based Requirements, still have 152 calendar days from July 1, 2020, or until November 30, 2020, to regain compliance with the Minimum Bid Price Requirement. The Company can regain compliance, either during the suspension or during the compliance period resuming after the suspension, by evidencing compliance with the Price-based Requirements for a minimum of 10 consecutive trading days. On October 29, 2020, at the Company’s Annual Meeting of Stockholders, the stockholders approved a proposal to extend the discretionary authority previously granted to the Board of Directors to effect a “reverse stock split,” at a specific ratio within a range of no split and one-for-thirty (1-for-30), with the exact ratio to be determined by the Board of Directors in its sole discretion on or before October 29, 2021. Since the Company does not intend to execute a reverse stock split prior to November 30, 2020, the Company expects to receive a notice of delisting from Nasdaq shortly after November 30, 2020 because the Company will not be in compliance with the Minimum Bid Price Requirement on November 30, 2020. The Company intends to appeal any notice of delisting that NASDAQ issues after November 30, 2020, as the Company has continuing discretionary authority to implement a reverse stock split (through October 29, 2021), which the Company may receive additional temporary relief (not to exceed 180 days from the date of the delisting notice) from NASDAQ. Such temporary relief, if granted, would allow the Company additional time to execute on its business initiatives to generate greater stockholder value and hopefully increase the share price of the Company’s common stock. During the appeal process, the Company’s shares will remain listed on NASDAQ.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC. The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2020. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, accruals for potential liabilities, valuing equity instruments issued during the period, and realization of deferred tax assets. Revenue Recognition The Company’s revenue is comprised of sales of medical foods, nutraceuticals and supplements to consumers through a direct sales/credit card process in the United States and through distributors outside the United States. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally. The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers Under the guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied. All products sold by the Company are distinct individual products and consist of medical foods, nutraceuticals, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Control of products sold transfers to customers upon shipment from the Company’s or suppliers’ facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payments for sales of medical foods and nutraceuticals are generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail medical foods customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical medical foods and medical device product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. The following table presents the Company’s revenues disaggregated by product line: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Medical foods and nutraceuticals $ 142,556 $ 112,957 $ 1,446,584 $ 317,338 Medical devices 110,632 44,705 237,136 337,531 Other - 3,500 6,100 9,800 $ 253,188 $ 161,162 $ 1,689,820 $ 664,669 The following table presents the Company’s revenues disaggregated by geography: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 North America $ 156,431 $ 129,992 $ 668,769 $ 401,379 Malaysia - - 890,000 - Asia 36,661 1,500 62,450 130,450 Europe and other 60,096 29,670 68,601 132,840 $ 253,188 $ 161,162 $ 1,689,820 $ 664,669 The Company’s medical foods and nutraceuticals revenues are derived from individual retail customers in North America and international distributors. A total of 61% of Medical foods and nutraceuticals revenues for the nine months ended September 30, 2020 were due to the sale, in June 2020, of a proprietary nutraceutical product to a Malaysian distributor. Medical devices revenues are derived from a worldwide customer base consisting of both retail customers and distributors. International customers contributed approximately 29% and 39% of Medical devices revenues for the nine months ended September 30, 2020 and 2019, respectively. Distributors contributed approximately 52% and 64% of Medical devices revenues for the nine months ended September 30, 2020 and 2019, respectively. During February 2020, the Company contracted with a Malaysian company to develop an immune-supportive formula for its consumer base. During the nine months ended September 30, 2020, the Company completed shipment of the product, received payment in full, and has recognized revenue for this order of $890,000. The sample product order is a proprietary immune-supportive formula that consists of a two-bottle package, each bottle containing different blends of certain ingredients the formulation of which is proprietary to the Malaysian company. The product is designed by the Malaysian company to boost immune system capability, which the Malaysian company intends to sell to its consumer base. Concentrations During the three months ended September 30, 2020, the Medical foods and nutraceuticals segment had no customers that accounted for more than 10% of the Company’s sales. During the three months ended September 30, 2020, the Medical devices segment had two customers that accounted for approximately 12% and 15% of the Company’s sales. No other customer accounted for more than 10% of sales in either period. During the nine months ended September 30, 2020, the Medical foods and nutraceuticals segment had one customer that accounted for approximately 53% of the Company’s sales. During the nine months ended September 30, 2020, the Medical devices segment had no customers that accounted for more than 10% of the Company’s sales. No other customer accounted for more than 10% of sales in either period. During the three months ended September 30, 2020, the Medical foods and nutraceuticals segment had two vendors that accounted for approximately 44% and 56% of all purchases. During the three months ended September 30, 2020, the Medical devices segment had three vendors that accounted for approximately 10%, 29%, and 42% of all purchases. No other vendors exceeded 10% of all purchases during any periods presented. During the nine months ended September 30, 2020, the Medical foods and nutraceuticals segment had three vendors that accounted for 20%, 28%, and 46% of all purchases. During the nine months ended September 30, 2020, the Medical devices segment had two vendors that accounted for approximately 18% and 55% of all purchases. No other vendors exceeded 10% of all purchases during any periods presented. Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures are expensed as incurred and totaled $109,803 and $138,613 for the nine months ended September 30, 2020 and 2019, respectively. Patent Costs The Company is the owner of four issued domestic patents, two pending domestic patent applications, one issued foreign patent in Europe and the United Kingdom, two issued foreign patents in Ireland, and one issued foreign patent in Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the nine months ended September 30, 2020 and 2019, patent costs were $99,589 and $80,879, respectively, and are included in general and administrative costs in the statements of operations. Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with ASC 718, Compensation-Stock Compensation Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and options that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive, as they decrease loss per share. The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: September 30, 2020 2019 Warrants 15,452,988 1,502,738 Options 3,919,167 2,712,500 19,372,155 4,215,238 Fair Value Measurements Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. As of September 30, 2020, and December 31, 2019, the Company’s balance sheets included Level 2 liabilities comprised of the fair value of warrant liabilities aggregating $7,519 and $13,323, respectively. Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January 1, 2021. The Company is assessing the impact ASU 2019-12 will have on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting for its convertible debt instruments. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption. The Company’s management does not believe that there are any recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Acquisition of NutriGuard

Acquisition of NutriGuard	9 Months Ended
Acquisition of NutriGuard	Sep. 30, 2020
Business Combinations [Abstract]
Acquisition of NutriGuard	3. Acquisition of NutriGuard Effective September 20, 2019 (the “Effective Date”), the Company’s newly-formed wholly-owned subsidiary, NutriGuard Formulations, Inc., a Delaware corporation, completed an asset purchase agreement (the “Asset Purchase Agreement”) with NutriGuard Research, Inc., a California corporation (“NutriGuard”), and NutriGuard’s sole shareholder, Mark McCarty. Pursuant to the Asset Purchase Agreement, the Company purchased specified assets of the NutriGuard brand and business, consisting primarily of inventory, trademarks, copyrights and other intellectual property. In exchange, the Company agreed to pay a 3% royalty, payable quarterly, to NutriGuard based on the operating results of the NutriGuard branded products in future periods, after $500,000 in specified gross revenues have been achieved by the Company. As of September 30, 2020 and December 31, 2019 no amounts were owed or accrued to NutriGuard. The following unaudited pro forma financial information gives effect to the Company’s acquisition of NutriGuard as if the acquisition had occurred on January 1, 2019 and had been included in the Company’s consolidated statements of operations for the three and nine months ended September 30, 2019: Three Months 2019 Pro forma net revenues $ 178,176 Pro forma net loss $ (2,338,296 ) Pro forma net loss per share $ (0.06 ) Nine months 2019 Pro forma net revenues $ 724,899 Pro forma net loss $ (6,815,355 ) Pro forma net loss per share $ (0.26 )

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories, net of reserves of $56,605 and $56,605, respectively, consisted of the following: September 30, December 31, 2020 2019 Raw materials $ 121,709 $ 246,875 Finished goods 1,162,464 64,066 $ 1,284,173 $ 310,941

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
Property and Equipment, Net	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, net Property and equipment consisted of the following: September 30, December 31, 2020 2019 Leasehold improvements $ 103,256 $ 98,357 Testing equipment 348,123 394,427 Furniture and fixtures 197,349 185,799 Computer equipment 68,460 68,460 Office equipment 9,835 8,193 727,023 755,236 Less accumulated depreciation and amortization (421,423 ) (380,598 ) $ 305,600 $ 374,638 For the nine months ended September 30, 2020 and 2019, depreciation expense was $45,552 and $48,836, respectively, of which $25,446 and $0 was included in research and development expense, $9,065 and $32,289 was included in sales and marketing expense, and $11,041 and $16,547 was included in general and administrative expense, respectively.

Lease Liabilities

Lease Liabilities	9 Months Ended
Lease Liabilities	Sep. 30, 2020
Leases [Abstract]
Lease Liabilities	6. Lease Liabilities In October 2012, the Company entered into a lease agreement for 9,605 square feet of office and warehouse space commencing March 1, 2013. Upon entering into the lease agreement, the Company paid a deposit of $47,449, of which $36,979 represented prepaid rent. As of September 30, 2020, $11,751 remained on deposit under the lease agreement. The lease (“Lease 1”) was renewed for an additional five years in 2018. As of September 30, 2020, remaining lease payments under Lease 1 averaged $13,146 per month through July 2023. In connection with the VectorVision acquisition on September 29, 2017, the Company assumed a lease agreement for 5,000 square feet of office and warehouse space which commenced on October 1, 2017. The lease (“Lease 2”) was renewed for an additional 65 months. As of September 30, 2020, remaining lease payments averaged $1,871 per month through February 2023. The leases have been accounted for in accordance with ASC 842, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the leases as operating leases and determined that the present value of Lease 1 at the inception of the lease was $639,520 using a discount rate of 3.9% and the present value of Lease 2 at the inception of the lease was $81,634 using a discount rate of 3.9%. The aggregate balance of the lease liabilities at December 31, 2019 was $586,315. During the nine months ended September 30, 2020, the Company made combined payments on both leases of $112,444 towards the lease liabilities. The aggregate balance of the lease liabilities at September 30, 2020 was $473,871, of which $159,962 was current. Combined rent expense for both leases for the nine months ended September 30, 2020 and 2019 was $128,150 and $130,742, respectively. The balance of the right-of-use asset as of December 31, 2019 was $572,714. During the nine months ended September 30, 2020, the Company reflected amortization of right-of-use asset of $115,037 related to the leases, resulting in a net asset balance of $457,677 as of September 30, 2020.

Settlement with Former Officer

Settlement with Former Officer	9 Months Ended
Settlement with Former Officer	Sep. 30, 2020
Settlement With Former Officer
Settlement with Former Officer	7. Settlement with Former Officer Effective June 15, 2020, Michael Favish resigned as Chief Executive Officer and as an employee of the Company and resigned from the Company’s Board of Directors. Terms of the settlement agreement between the parties included the continuation of his previous salary of $325,000 during the twelve months subsequent to his resignation. The $325,000 of aggregated settlement payments was recorded in costs related to resignation of former officer expense in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2020. As of September 30, 2020, $230,208 of the amount due remains accrued on our condensed consolidated balance sheet. In addition, 833,333 options previously granted to the former officer were forfeited (See Note 8).

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Common Stock During the nine months ended September 30, 2020, the Company issued 25,000 fully vested shares of common stock for services rendered and recognized $12,325 in stock compensation expense related to these shares. Warrants A summary of the Company’s warrant activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2019 28,802,738 0.38 4.91 Granted - - - Forfeitures - - - Expirations (30,000 ) (1.50 ) - Exercised (13,319,750 ) (0.34 ) - September 30, 2020, all exercisable 15,452,988 $ 0.39 4.06 The exercise prices of warrants outstanding and exercisable as of September 30, 2020 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 12,020,250 $ 0.34 1,960,000 0.44 1,040,000 0.50 226,200 0.59 35,000 1.50 109,038 2.88 62,500 5.00 15,452,988 During the nine months ended September 30, 2020, investors exercised a total of 13,319,750 warrants for 13,319,750 shares of common stock. The warrants were exercisable for $0.34 per share, which resulted in cash proceeds to the Company of $4,555,354. As of September 30, 2020, the Company had an aggregate of 15,452,988 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $0.39 and a weighted average remaining life of 4.06 years. The aggregate intrinsic value of warrants outstanding as of September 30, 2020 was zero. Warrant Liability On April 9, 2019, the Company issued 62,500 warrants with an exercise price of $5.00 per share to the underwriter in connection with the Company’s initial public offering (“IPO”). The Company accounted for these warrants as a derivative liability in the financial statements at June 30, 2019 because they were associated with the IPO, a registered offering, and the settlement provisions contained language that the shares underlying the warrants are required to be registered. The fair value of the warrants is remeasured at each reporting period, and the change in the fair value is recognized in earnings in the accompanying Statements of Operations. The fair value of the warrants at December 31, 2019 was $13,323. As of September 30, 2020, the fair value of the warrants was determined to be $7,519 and the change in fair value of $11,892 was recognized in the accompanying statements of operations. The fair value of the warrant liability was determined at the following reporting dates using the Black-Scholes-Merton option pricing model and the following assumptions: Warrant Liability Warrant Liability As of September 30, 2020 December 31, 2019 Stock price $ 0.20 $ 0.22 Risk free interest rate 0.16 % 1.62 % Expected volatility 148 % 145 % Expected life in years 3.51 4.26 Expected dividend yield 0 % 0 % Number of warrants 62,500 62,500 Fair value of warrants $ 7,519 $ 13,323 Stock Options A summary of the Company’s stock option activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2019 2,962,500 2.94 3.64 Granted 1,790,000 0.90 9.71 Forfeitures (833,333 ) - - Expirations - - - Exercised - - - September 30, 2020, outstanding 3,919,167 $ 1.69 6.01 September 30, 2020, exercisable 2,327,500 $ 2.23 3.66 The exercise prices of options outstanding and exercisable as of September 30, 2020 are as follows: Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 250,000 218,70 $ 0.25 30,000 30,000 0.32 250,000 93,750 0.39 10,000 10,000 0.41 100,000 50,000 0.54 1,500,000 145,833 1.00 625,000 625,000 2.00 62,500 62,500 2.30 675,000 675,000 2.50 416,667 416,667 4.40 3,919,167 2,327,500 The Company accounts for share-based payments in accordance with ASC 718 wherein grants are measured at the grant date fair value and charged to operations over the vesting periods. During the nine months ended September 30, 2020, the Company granted options to purchase 1,290,000 shares of common stock to six employees with a grant date fair value of $581,128. The options have an exercise price of $0.32 to $1.00 per share. Options for 250,000 shares vest on a quarterly basis over two years and options for 40,000 shares vest in full six months after the grant date. Options for 1,000,000 shares vest ratably over three years. On June 30, 2020, the Company granted options to purchase 500,000 shares of common stock to the members of the Company’s Board of Directors with a grant date fair value of $216,093. The options have an exercise price of $1.00 per share. The options vest on a quarterly basis over two years beginning three months after the grant date. During the nine months ended September 30, 2020 and 2019, the Company recognized aggregate stock-compensation expense of $227,011 and $1,964,432, based upon stock prices ranging from $0.25 to $3.30 per share. As of September 30, 2020, the Company had an aggregate of 1,591,667 remaining unvested options outstanding, with a fair value of $715,612, weighted average exercise price of $0.91, and weighted average remaining life of 9.45 years. The aggregate intrinsic value of options outstanding as of September 30, 2020 was zero. The aggregate intrinsic value of unvested options outstanding as of September 30, 2020 was zero. In connection with a separation agreement entered into with Michael Favish, former officer (see Note 7), the expiration date of his vested stock options was extended for twelve months from June 15, 2020. In accordance with ASC 718, the extension of the exercise period for the vested options constitutes a modification of the original option agreement. In accounting for the modification, the Company calculated the fair value of the vested options immediately before modification using current valuation inputs including the Company’s closing stock price of $0.49 on June 15, 2020, a volatility metric of 142%, and a risk-free interest rate of 0.22%. The Company also calculated the fair value of the vested options immediately following the modification using the extended 12-month exercise period. An incremental stock compensation charge of $24,359 was recorded in costs related to resignation of former officer. Mr. Favish’s unvested options of 833,333 at the time of his separation were forfeited. All compensation from prior periods related to these unvested options was reversed, resulting in an adjustment to stock compensation expense during the nine months ended September 30, 2020 of $(965,295), which was recorded in costs related to resignation of former officer. In connection with his separation, the expiration date of Mr. Favish’s vested stock options was extended for twelve months from June 15, 2020. In accordance with ASC 718, the extension of the exercise period for the vested options constitutes a modification of the original option agreement. In accounting for the modification, the Company calculated the fair value of the vested options immediately before modification using current valuation inputs including the Company’s closing stock price of $0.49 on June 15, 2020, a volatility metric of 142%, and a risk-free interest rate of 0.22%. The Company also calculated the fair value of the vested options immediately following the modification using the extended 12-month exercise period. An incremental stock compensation charge of $24,359 was recorded in costs related to resignation of former officer. Mr. Favish’s unvested options at the time of his separation were forfeited. All compensation from prior periods related to these unvested options was reversed, resulting in an adjustment to stock compensation expense during the nine months ended September 30, 2020 of $(965,295), which was recorded in costs related to resignation of former officer.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions During the nine months ended September 30, 2020 and 2019, the Company incurred and paid salaries of $50,313 and $113,583, respectively, to Karen Favish, spouse of Michael Favish, the Company’s former Chief Executive Officer. During the nine months ended September 30, 2020 and 2019, the Company incurred and paid salaries of $45,000 and $37,147, respectively, to Kristine Townsend, spouse of the Company’s former Controller and Chief Accounting Officer John Townsend. During the nine months ended September 30, 2020 and 2019, the Company paid consulting expenses of $45,500 and $88,500, respectively, to Ceatus Media Group, LLC, a web design company owned by Chief Science Officer and Interim President and Chief Executive Officer Dr. David Evans and his spouse Tamara Evans. During the nine months ended September 30, 2020 and 2019, the Company paid building rent of $16,114 and $15,648, respectively, to DWT Evans LLC, a company owned by David Evans and his spouse Tamara Evans. When the Company acquired VectorVision, it also acquired AcQviz from Dr. Evans, which is a patented methodology for auto-calibrating and standardizing the testing light level for computer generated vision testing systems. Dr. Evans is entitled to receive a royalty on net revenue from AcQviz. As part of the development of the CSV-2000, AcQviz was embedded in the product by Radiant Technologies, Inc. in exchange for a 3% royalty on the sales of AcQviz. Radiant Technologies is owned by Joseph T. Evans, the brother of Dr. David Evans.

Segment Reporting

Segment Reporting	9 Months Ended
Segment Reporting	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	10. Segment Reporting The Company determined its reporting units are as follows in accordance with ASC 280, “Segment Reporting” (“ASC 280”). The Company currently operate in two reportable segments: Medical foods and nutraceuticals and Medical devices. The. Medical foods and nutraceuticals segment provides a portfolio of science-based, clinically supported nutrition, medical foods, and supplements. The Company’s products include, among others, Lumega-Z, Glaucocetin, ImmuneSF. The Medical devices segment includes a portfolio of medical diagnostic devices currently focused on the ocular space and the Company is believed to be the industry leader in contrast testing. The medical devices and accessories are used to measure visual function and certain anatomical features of the eye. These measures detect early disease and monitor changes over time, and the results due to nutritional regimens. The Company’s products include VectorVision CSV-1000, CSV-1000HGT, CSV-2000, ESV-3000 and associated accessories as well as the MapcatSF. The accounting policies of the Company’s reportable segments are the same as those described in the summary of significant accounting policies (Note 2). Certain corporate general and administrative expenses, including general overhead functions such as information systems, accounting, human resources, Board of Director fees, corporate legal fees, other compliance costs and certain administrative expenses, as well as interest and tax expense, are not allocated to the segments. The reportable segments are each managed separately because they manufacture and distribute distinct products or provide services with different processes. All reported segment revenues are derived from external customers. The segments are based on the discrete financial information reviewed by the Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), to make resource allocation decisions and to evaluate performance. For the Three Months Ended September 30, 2020 Corporate Medical Medical Devices Total Revenue $ - $ 142,556 $ 110,632 $ 253,188 Cost of goods sold - 68,956 45,157 114,113 Gross profit - 73,600 65,475 139,075 Operating expenses 1,202,402 1,081,897 6,446 2,290,745 (Loss) income from operations $ (1,202,402 ) $ (1,008,296 ) $ 59,028 $ (2,151,670 ) For the Three Months Ended September 30, 2019 Corporate Medical Medical Devices Total Revenue $ 3,5000 $ 112,957 $ 44,705 $ 161,162 Cost of goods sold 1,422 41,655 27,922 70,999 Gross profit 2,078 71,302 16,783 90,163 Operating expenses 1,235,389 1,124,462 142,800 2,502,651 Loss from operations $ (1,233,311 ) $ (1,053,160 ) $ (126,017 ) $ (2,412,488 ) For the Nine Months Ended September 30, 2020 Corporate Medical Medical Devices Total Revenue $ 6,100 $ 1,446,584 $ 237,136 $ 1,689,820 Cost of goods sold 2,477 764,246 101,077 867,800 Gross profit 3,623 682,338 136,059 822,020 Operating expenses 2,655,107 3,146,514 216,516 6,018,137 Loss from operations $ (2,651,484 ) $ (2,464,176 ) $ (80,457 ) $ (5,196,117 ) For the Nine Months Ended September 30, 2019 Corporate Medical Medical Devices Total Revenue $ 9,800 $ 317,338 $ 337,531 $ 664,669 Cost of goods sold 3,981 120,608 136,958 261,547 Gross profit 5,819 196,730 200,573 403,122 Operating expenses 3,195,227 3,127,782 490,023 6,813,032 Loss from operations $ (3,189,408 ) $ (2,931,052 ) $ (289,450 ) $ (6,409,910 ) The following tables set forth the Company’s total assets by segment. Intersegment balances and transactions have been removed: As of September 30, 2020 Corporate Medical Medical Devices Total Current assets Cash $ 9,795,441 $ $ - $ 9,795,441 Inventories - 922,256 361,917 1,284,172 Other 1,600 150,659 102,211 254,471 Total current assets 9,797,041 1,072,915 464,128 11,334,084 Right-of-use asset, net - 408,686 48,991 457,677 Property and equipment, net - 146,163 159,437 305,600 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 9,797,041 $ 1,689,515 $ 672,555 $ 12,159,112 As of December 31, 2019 Corporate Medical Medical Devices Total Current assets Cash $ 11,115,502 $ - $ - $ 11,115,502 Inventories 5,003 126,708 179,230 310,941 Other 7,399 219,223 214,653 441,275 Total current assets 11,127,904 345,931 393,883 11,867,718 Right-of-use asset - 509,464 63,250 572,714 Property and equipment, net 70,542 148,514 155,582 374,638 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 11,198,446 $ 1,065,660 $ 612,715 $ 12,876,821

Contingencies

Contingencies	9 Months Ended
Contingencies	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	11. Contingencies The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. As of September 30, 2020, management is not aware of any pending or threatened matters that it believes warrant a contingency reserve, and therefore there is no provision in the Company’s financial statements with respect to such matters.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC. The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2020.
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, accruals for potential liabilities, valuing equity instruments issued during the period, and realization of deferred tax assets.
Revenue Recognition	Revenue Recognition The Company’s revenue is comprised of sales of medical foods, nutraceuticals and supplements to consumers through a direct sales/credit card process in the United States and through distributors outside the United States. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally. The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers Under the guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied. All products sold by the Company are distinct individual products and consist of medical foods, nutraceuticals, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Control of products sold transfers to customers upon shipment from the Company’s or suppliers’ facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payments for sales of medical foods and nutraceuticals are generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers. The Company provides a 30-day right of return to its retail medical foods customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical medical foods and medical device product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. The following table presents the Company’s revenues disaggregated by product line: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Medical foods and nutraceuticals $ 142,556 $ 112,957 $ 1,446,584 $ 317,338 Medical devices 110,632 44,705 237,136 337,531 Other - 3,500 6,100 9,800 $ 253,188 $ 161,162 $ 1,689,820 $ 664,669 The following table presents the Company’s revenues disaggregated by geography: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 North America $ 156,431 $ 129,992 $ 668,769 $ 401,379 Malaysia - - 890,000 - Asia 36,661 1,500 62,450 130,450 Europe and other 60,096 29,670 68,601 132,840 $ 253,188 $ 161,162 $ 1,689,820 $ 664,669 The Company’s medical foods and nutraceuticals revenues are derived from individual retail customers in North America and international distributors. A total of 61% of Medical foods and nutraceuticals revenues for the nine months ended September 30, 2020 were due to the sale, in June 2020, of a proprietary nutraceutical product to a Malaysian distributor. Medical devices revenues are derived from a worldwide customer base consisting of both retail customers and distributors. International customers contributed approximately 29% and 39% of Medical devices revenues for the nine months ended September 30, 2020 and 2019, respectively. Distributors contributed approximately 52% and 64% of Medical devices revenues for the nine months ended September 30, 2020 and 2019, respectively. During February 2020, the Company contracted with a Malaysian company to develop an immune-supportive formula for its consumer base. During the nine months ended September 30, 2020, the Company completed shipment of the product, received payment in full, and has recognized revenue for this order of $890,000. The sample product order is a proprietary immune-supportive formula that consists of a two-bottle package, each bottle containing different blends of certain ingredients the formulation of which is proprietary to the Malaysian company. The product is designed by the Malaysian company to boost immune system capability, which the Malaysian company intends to sell to its consumer base.
Concentrations	Concentrations During the three months ended September 30, 2020, the Medical foods and nutraceuticals segment had no customers that accounted for more than 10% of the Company’s sales. During the three months ended September 30, 2020, the Medical devices segment had two customers that accounted for approximately 12% and 15% of the Company’s sales. No other customer accounted for more than 10% of sales in either period. During the nine months ended September 30, 2020, the Medical foods and nutraceuticals segment had one customer that accounted for approximately 53% of the Company’s sales. During the nine months ended September 30, 2020, the Medical devices segment had no customers that accounted for more than 10% of the Company’s sales. No other customer accounted for more than 10% of sales in either period. During the three months ended September 30, 2020, the Medical foods and nutraceuticals segment had two vendors that accounted for approximately 44% and 56% of all purchases. During the three months ended September 30, 2020, the Medical devices segment had three vendors that accounted for approximately 10%, 29%, and 42% of all purchases. No other vendors exceeded 10% of all purchases during any periods presented. During the nine months ended September 30, 2020, the Medical foods and nutraceuticals segment had three vendors that accounted for 20%, 28%, and 46% of all purchases. During the nine months ended September 30, 2020, the Medical devices segment had two vendors that accounted for approximately 18% and 55% of all purchases. No other vendors exceeded 10% of all purchases during any periods presented.
Research and Development Costs	Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures are expensed as incurred and totaled $109,803 and $138,613 for the nine months ended September 30, 2020 and 2019, respectively.
Patent Costs	Patent Costs The Company is the owner of four issued domestic patents, two pending domestic patent applications, one issued foreign patent in Europe and the United Kingdom, two issued foreign patents in Ireland, and one issued foreign patent in Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the nine months ended September 30, 2020 and 2019, patent costs were $99,589 and $80,879, respectively, and are included in general and administrative costs in the statements of operations.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from nonemployees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with ASC 718, Compensation-Stock Compensation
Net Loss Per Share	Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and options that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive, as they decrease loss per share. The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: September 30, 2020 2019 Warrants 15,452,988 1,502,738 Options 3,919,167 2,712,500 19,372,155 4,215,238
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows: Level 1 – quoted prices in active markets for identical assets or liabilities. Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. Our non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. As of September 30, 2020, and December 31, 2019, the Company’s balance sheets included Level 2 liabilities comprised of the fair value of warrant liabilities aggregating $7,519 and $13,323, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard will be effective beginning January 1, 2021. The Company is assessing the impact ASU 2019-12 will have on its consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As a smaller reporting company, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 will be effective January 1, 2024, for the Company. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting for its convertible debt instruments. The effect will largely depend on the composition and terms of the financial instruments at the time of adoption. The Company’s management does not believe that there are any recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by product line: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Medical foods and nutraceuticals $ 142,556 $ 112,957 $ 1,446,584 $ 317,338 Medical devices 110,632 44,705 237,136 337,531 Other - 3,500 6,100 9,800 $ 253,188 $ 161,162 $ 1,689,820 $ 664,669 The following table presents the Company’s revenues disaggregated by geography: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 North America $ 156,431 $ 129,992 $ 668,769 $ 401,379 Malaysia - - 890,000 - Asia 36,661 1,500 62,450 130,450 Europe and other 60,096 29,670 68,601 132,840 $ 253,188 $ 161,162 $ 1,689,820 $ 664,669
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: September 30, 2020 2019 Warrants 15,452,988 1,502,738 Options 3,919,167 2,712,500 19,372,155 4,215,238

Acquisition of NutriGuard (Tabl

Acquisition of NutriGuard (Tables)	9 Months Ended
Acquisition of NutriGuard (Tables)	Sep. 30, 2020
Business Combinations [Abstract]
Schedule of Pro Forma Financial Information	The following unaudited pro forma financial information gives effect to the Company’s acquisition of NutriGuard as if the acquisition had occurred on January 1, 2019 and had been included in the Company’s consolidated statements of operations for the three and nine months ended September 30, 2019: Three Months 2019 Pro forma net revenues $ 178,176 Pro forma net loss $ (2,338,296 ) Pro forma net loss per share $ (0.06 ) Nine months 2019 Pro forma net revenues $ 724,899 Pro forma net loss $ (6,815,355 ) Pro forma net loss per share $ (0.26 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories, net of reserves of $56,605 and $56,605, respectively, consisted of the following: September 30, December 31, 2020 2019 Raw materials $ 121,709 $ 246,875 Finished goods 1,162,464 64,066 $ 1,284,173 $ 310,941

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
Property and Equipment, Net (Tables)	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: September 30, December 31, 2020 2019 Leasehold improvements $ 103,256 $ 98,357 Testing equipment 348,123 394,427 Furniture and fixtures 197,349 185,799 Computer equipment 68,460 68,460 Office equipment 9,835 8,193 727,023 755,236 Less accumulated depreciation and amortization (421,423 ) (380,598 ) $ 305,600 $ 374,638

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2020
Equity [Abstract]
Schedule of Warrants Activity	A summary of the Company’s warrant activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2019 28,802,738 0.38 4.91 Granted - - - Forfeitures - - - Expirations (30,000 ) (1.50 ) - Exercised (13,319,750 ) (0.34 ) - September 30, 2020, all exercisable 15,452,988 $ 0.39 4.06
Schedule of Exercise Price of Warrants Outstanding and Exercisable	The exercise prices of warrants outstanding and exercisable as of September 30, 2020 are as follows: Warrants Outstanding and Exercisable (Shares) Exercise Prices 12,020,250 $ 0.34 1,960,000 0.44 1,040,000 0.50 226,200 0.59 35,000 1.50 109,038 2.88 62,500 5.00 15,452,988
Schedule of Fair Value Assumptions of Warrant Liability	The fair value of the warrant liability was determined at the following reporting dates using the Black-Scholes-Merton option pricing model and the following assumptions: Warrant Liability Warrant Liability As of September 30, 2020 December 31, 2019 Stock price $ 0.20 $ 0.22 Risk free interest rate 0.16 % 1.62 % Expected volatility 148 % 145 % Expected life in years 3.51 4.26 Expected dividend yield 0 % 0 % Number of warrants 62,500 62,500 Fair value of warrants $ 7,519 $ 13,323
Schedule of Share-based Compensation, Stock Options, Activity	A summary of the Company’s stock option activity is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2019 2,962,500 2.94 3.64 Granted 1,790,000 0.90 9.71 Forfeitures (833,333 ) - - Expirations - - - Exercised - - - September 30, 2020, outstanding 3,919,167 $ 1.69 6.01 September 30, 2020, exercisable 2,327,500 $ 2.23 3.66
Schedule of Exercise Price of Options Outstanding and Exercisable	The exercise prices of options outstanding and exercisable as of September 30, 2020 are as follows: Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 250,000 218,70 $ 0.25 30,000 30,000 0.32 250,000 93,750 0.39 10,000 10,000 0.41 100,000 50,000 0.54 1,500,000 145,833 1.00 625,000 625,000 2.00 62,500 62,500 2.30 675,000 675,000 2.50 416,667 416,667 4.40 3,919,167 2,327,500

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
Segment Reporting (Tables)	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The segments are based on the discrete financial information reviewed by the Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), to make resource allocation decisions and to evaluate performance. For the Three Months Ended September 30, 2020 Corporate Medical Medical Devices Total Revenue $ - $ 142,556 $ 110,632 $ 253,188 Cost of goods sold - 68,956 45,157 114,113 Gross profit - 73,600 65,475 139,075 Operating expenses 1,202,402 1,081,897 6,446 2,290,745 (Loss) income from operations $ (1,202,402 ) $ (1,008,296 ) $ 59,028 $ (2,151,670 ) For the Three Months Ended September 30, 2019 Corporate Medical Medical Devices Total Revenue $ 3,5000 $ 112,957 $ 44,705 $ 161,162 Cost of goods sold 1,422 41,655 27,922 70,999 Gross profit 2,078 71,302 16,783 90,163 Operating expenses 1,235,389 1,124,462 142,800 2,502,651 Loss from operations $ (1,233,311 ) $ (1,053,160 ) $ (126,017 ) $ (2,412,488 ) For the Nine Months Ended September 30, 2020 Corporate Medical Medical Devices Total Revenue $ 6,100 $ 1,446,584 $ 237,136 $ 1,689,820 Cost of goods sold 2,477 764,246 101,077 867,800 Gross profit 3,623 682,338 136,059 822,020 Operating expenses 2,655,107 3,146,514 216,516 6,018,137 Loss from operations $ (2,651,484 ) $ (2,464,176 ) $ (80,457 ) $ (5,196,117 ) For the Nine Months Ended September 30, 2019 Corporate Medical Medical Devices Total Revenue $ 9,800 $ 317,338 $ 337,531 $ 664,669 Cost of goods sold 3,981 120,608 136,958 261,547 Gross profit 5,819 196,730 200,573 403,122 Operating expenses 3,195,227 3,127,782 490,023 6,813,032 Loss from operations $ (3,189,408 ) $ (2,931,052 ) $ (289,450 ) $ (6,409,910 ) The following tables set forth the Company’s total assets by segment. Intersegment balances and transactions have been removed: As of September 30, 2020 Corporate Medical Medical Devices Total Current assets Cash $ 9,795,441 $ $ - $ 9,795,441 Inventories - 922,256 361,917 1,284,172 Other 1,600 150,659 102,211 254,471 Total current assets 9,797,041 1,072,915 464,128 11,334,084 Right-of-use asset, net - 408,686 48,991 457,677 Property and equipment, net - 146,163 159,437 305,600 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 9,797,041 $ 1,689,515 $ 672,555 $ 12,159,112 As of December 31, 2019 Corporate Medical Medical Devices Total Current assets Cash $ 11,115,502 $ - $ - $ 11,115,502 Inventories 5,003 126,708 179,230 310,941 Other 7,399 219,223 214,653 441,275 Total current assets 11,127,904 345,931 393,883 11,867,718 Right-of-use asset - 509,464 63,250 572,714 Property and equipment, net 70,542 148,514 155,582 374,638 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 11,198,446 $ 1,065,660 $ 612,715 $ 12,876,821

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($)	Oct. 29, 2020	Sep. 20, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Net loss			$ (2,143,494)	$ (707,160)	$ (2,346,913)	$ (2,385,371)	$ (3,052,078)	$ (1,385,099)	$ (5,197,567)	$ (6,822,553)
Cash utilized in operating activities									$ (5,840,682)	$ (4,189,050)
Subsequent Event [Member]
Reverse stock split	one-for-thirty (1-for-30)
Nasdaq Stock Market LLC [Member]
Closing bid price per share		$ 1
Minimum bid price requirement, description		In accordance with Nasdaq listing rules, the Company was provided an initial period of 180 calendar days, or until March 18, 2020, to regain compliance with the Minimum Bid Price Requirement. The Company was unable to regain compliance with the Minimum Bid Price Requirement during the initial period and was eligible for an additional 180 calendar day compliance period.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Research and development costs	$ 34,034	$ 31,897		$ 109,803	$ 138,613
Patent costs	$ 99,589	80,879		99,589	$ 80,879
Fair value of warrant liabilities			$ 359,683	$ 7,519		$ 13,323
Purchases [Member] \| No Vendor [Member]
Concentration risk, percentage	10.00%			10.00%
Medical Foods and Nutraceuticals [Member] \| Purchases [Member] \| Vendor One [Member]
Concentration risk, percentage	44.00%			20.00%
Medical Foods and Nutraceuticals [Member] \| Purchases [Member] \| Vendor Two [Member]
Concentration risk, percentage	56.00%			28.00%
Medical Foods and Nutraceuticals [Member] \| Purchases [Member] \| Vendor Three [Member]
Concentration risk, percentage				46.00%
Medical Foods and Nutraceuticals [Member] \| Individual Retail Customers [Member]
Concentration risk, percentage				61.00%
Medical Foods and Nutraceuticals [Member] \| No Customer [Member] \| Sales Revenue [Member]
Concentration risk, percentage	10.00%
Medical Foods and Nutraceuticals [Member] \| One Customer [Member] \| Sales Revenue [Member]
Concentration risk, percentage	12.00%			53.00%
Medical Foods and Nutraceuticals [Member] \| Two customer [Member] \| Sales Revenue [Member]
Concentration risk, percentage	15.00%
Medical Foods and Nutraceuticals [Member] \| No Other Customers [Member] \| Sales Revenue [Member]
Concentration risk, percentage	10.00%			10.00%
Medical Foods and Nutraceuticals [Member] \| No Customers [Member] \| Sales Revenue [Member]
Concentration risk, percentage				10.00%
Medical Devices [Member] \| Purchases [Member] \| Vendor One [Member]
Concentration risk, percentage	10.00%			18.00%
Medical Devices [Member] \| Purchases [Member] \| Vendor Two [Member]
Concentration risk, percentage	29.00%			55.00%
Medical Devices [Member] \| Purchases [Member] \| Vendor Three [Member]
Concentration risk, percentage	42.00%
Medical Devices [Member] \| International Customers [Member]
Concentration risk, percentage				29.00%	39.00%
Medical Devices [Member] \| Distributors [Member]
Concentration risk, percentage				52.00%	64.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue by Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues	$ 253,188	$ 161,162	$ 1,689,820	$ 664,669
Medical Foods and Nutraceuticals [Member]
Revenues	142,556	112,957	1,446,584	317,338
Medical Devices [Member]
Revenues	110,632	44,705	237,136	337,531
Other [Member]
Revenues		$ 3,500	$ 6,100	$ 9,800

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Disaggregation of Revenue by Geography (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 253,188	$ 161,162	$ 1,689,820	$ 664,669
North America [Member]
Revenue	156,431	129,992	668,769	401,379
Malaysia [Member]
Revenue			890,000
Asia [Member]
Revenue	36,661	1,500	62,450	130,450
Europe and Other [Member]
Revenue	$ 60,096	$ 29,670	$ 68,601	$ 132,840

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive securities excluded from computation of earnings per share	19,372,155	4,215,238
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	15,452,988	1,502,738
Options [Member]
Antidilutive securities excluded from computation of earnings per share	3,919,167	2,712,500

Acquisition of NutriGuard (Deta

Acquisition of NutriGuard (Details Narrative) - USD ($)	Sep. 20, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Gross profit		$ 139,075	$ 90,163	$ 822,020	$ 403,122
NutriGuard Research, Inc [Member] \| Asset Purchase Agreement [Member]
Royalty percentage	3.00%
Gross profit	$ 500,000

Acquisition of NutriGuard - Sch

Acquisition of NutriGuard - Schedule of Pro Forma Financial Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Business Combinations [Abstract]
Pro forma net revenues	$ 178,176	$ 724,899
Pro forma net loss attributable to common shareholders	$ (2,338,296)	$ (6,815,355)
Pro forma net loss per share	$ (0.06)	$ (0.26)

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories, net of reserves	$ 56,605	$ 56,605

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 121,709	$ 246,875
Finished goods	1,162,464	64,066
Inventory, net	$ 1,284,173	$ 310,941

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	9 Months Ended
Property and Equipment, Net (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Depreciation expense	$ 45,552	$ 48,836
Research and Development Expense [Member]
Depreciation expense	25,446	0
Sales and Marketing Expense [Member]
Depreciation expense	9,065	32,289
General and Administrative Expense [Member]
Depreciation expense	$ 11,041	$ 16,547

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Property, plant and equipment, gross	$ 727,023	$ 755,236
Less accumulated depreciation and amortization	(421,423)	(380,598)
Property, plant and equipment, net	305,600	374,638
Leasehold Improvements [Member]
Property, plant and equipment, gross	103,256	98,357
Testing Equipment [Member]
Property, plant and equipment, gross	348,123	394,427
Furniture and Fixtures [Member]
Property, plant and equipment, gross	197,349	185,799
Computer Equipment [Member]
Property, plant and equipment, gross	68,460	68,460
Office Equipment [Member]
Property, plant and equipment, gross	$ 9,835	$ 8,193

Lease Liabilities (Details Narr

Lease Liabilities (Details Narrative)	1 Months Ended	9 Months Ended
Lease Liabilities (Details Narrative)	Oct. 31, 2012USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Sep. 29, 2017ft²
Lease liabilities		$ 473,871		$ 586,315
Lease liabiliies, current		159,962		151,568
Rent expense		128,150	$ 130,742
Right of use asset, net		457,677		$ 572,714
Amortization of right of use asset		115,037	$ 93,222
Lease 1 [Member]
Fair value of lease		$ 639,520
Lease discount rate		3.90%
Lease 2 [Member]
Fair value of lease		$ 81,634
Lease discount rate		3.90%
Lease 1 & 2 [Member]
Monthly lease payments		$ 112,444
Lease Agreement [Member]
Area of Land \| ft²	9,605
Deposit paid for lease	$ 47,449	11,751
Prepaid rent	$ 0
Renewal of lease term				5 years
Lease Agreement [Member] \| VectorVision, Inc [Member]
Area of Land \| ft²					5,000
Renewal of lease term					65 months
Lease Agreement [Member] \| Through July 2023 [Member]
Monthly lease payments		13,146
Lease Agreement [Member] \| Through February 2023 [Member] \| VectorVision, Inc [Member]
Monthly lease payments		$ 1,871

Settlement with Former Officer

Settlement with Former Officer (Details Narrative) - USD ($)	Jun. 15, 2020	Sep. 30, 2020	Dec. 31, 2019
Due to former officers		$ 230,208
Unvested options forfeited		833,333
Michael Favish [Member]
Former officers costs		$ 325,000
Michael Favish [Member] \| Settlement Agreement [Member] \| Tewlve Months [Member]
Payments to former officers	$ 325,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Jun. 15, 2020	Apr. 09, 2019	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Stock compensation expense							$ 239,336	$ 299,684
Proceeds from warrants exercise							$ 4,555,354	154,375
Warrants outstanding			62,500				62,500		62,500
Fair value of warrants						$ 359,683	$ 7,519		$ 13,323
Change in fair value of warrants - derivative liability			$ (11,892)		(31,322)		$ (5,804)	(259,154)
Shares options, granted							1,790,000
Unvested options forfeited							833,333
Recognized stock compensation expense							$ (965,295)
Based Upon Stock Prices [Member]
Stock compensation expense							$ 227,011	$ 1,964,432
Minimum [Member] \| Based Upon Stock Prices [Member]
Stock price			$ 0.25				$ 0.25
Maximum [Member] \| Based Upon Stock Prices [Member]
Stock price			$ 3.30				$ 3.30
Investors [Member]
Number of warrants exercised							13,319,750
Warrants to purchase common stock			13,319,750				13,319,750
Warrant exercisable price per share			$ 0.34				$ 0.34
Proceeds from warrants exercise							$ 4,555,354
Underwriters [Member] \| IPO [Member]
Warrant exercisable price per share		$ 5
Warrants issued		62,500
Six Employees [Member]
Shares options, granted							1,290,000
Grant date fair value of options granted							$ 581,128
Option vesting period							2 years
Six Employees [Member] \| Vest On a Quarterly Basis [Member]
Number of options vested							250,000
Six Employees [Member] \| Vest in Full Six Months [Member]
Number of options vested							40,000
Six Employees [Member] \| Over Three Years [Member]
Number of options vested							1,000,000
Six Employees [Member] \| Minimum [Member]
Stock option, exercise price per share							$ 0.32
Six Employees [Member] \| Maximum [Member]
Stock option, exercise price per share							$ 1
Board of Directors [Member]
Shares options, granted							500,000
Grant date fair value of options granted							$ 216,093
Stock option, exercise price per share							$ 1
Option vesting period							2 years
Michael Favish [Member]
Stock compensation expense							$ 24,359
Closing stock price	$ 0.49
Volatility metric	142.00%
Risk free interest rate	0.22%
Common Stock [Member]
Stock issued during period for services, shares				25,000		54,387	25,000
Stock compensation expense							$ 12,325
Fair value of warrants
Warrants [Member]
Warrant exercisable price per share			$ 0.39				$ 0.39
Warrants outstanding			15,452,988				15,452,988
Weighted average remaining life of warrants			4 years 22 days				4 years 22 days
Aggregate intrinsic value of warrants			$ 0				$ 0
Fair value of warrants							7,519		$ 13,323
Change in fair value of warrants - derivative liability							$ 11,892
Unvested Options [Member]
Number of unvested options outstanding			1,591,667				1,591,667
Number of unvested options outstanding, value			$ 715,612				$ 715,612
Unvested options, weighted average exercise price			$ 0.91				$ 0.91
Unvested options, weighted average remaining life							9 years 5 months 12 days
Aggregate intrinsic value of options outstanding			$ 0				$ 0
Unvested options, aggregate intrinsic value			$ 0				$ 0

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Shares, Ending Balance	15,452,988
Warrants [Member]
Shares, Beginning Balance	28,802,738
Shares, Granted
Shares, Forfeitures
Shares, Expirations	(30,000)
Shares, Exercised	(13,319,750)
Shares, Ending Balance	15,452,988
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 0.38
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Forfeitures \| $ / shares
Weighted Average Exercise Price, Expirations \| $ / shares	(1.50)
Weighted Average Exercise Price, Exercised \| $ / shares	(0.34)
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 0.39
Weighted Average Remaining Contractual Term (Years), Beginning Balance	4 years 10 months 28 days
Weighted Average Remaining Contractual Term (Years), Granted	0 years
Weighted Average Remaining Contractual Term (Years), Ending Balance	4 years 22 days

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Exercise Price of Warrants Outstanding and Exercisable (Details)	Sep. 30, 2020$ / sharesshares
Warrants Outstanding and Exercisable (Shares)	15,452,988
Warrant One [Member]
Warrants Outstanding and Exercisable (Shares)	12,020,250
Exercise Prices \| $ / shares	$ 0.34
Warrant Two [Member]
Warrants Outstanding and Exercisable (Shares)	1,960,000
Exercise Prices \| $ / shares	$ 0.44
Warrant Three [Member]
Warrants Outstanding and Exercisable (Shares)	1,040,000
Exercise Prices \| $ / shares	$ 0.5
Warrant Four [Member]
Warrants Outstanding and Exercisable (Shares)	226,200
Exercise Prices \| $ / shares	$ 0.59
Warrant Five [Member]
Warrants Outstanding and Exercisable (Shares)	35,000
Exercise Prices \| $ / shares	$ 1.5
Warrant Six [Member]
Warrants Outstanding and Exercisable (Shares)	109,038
Exercise Prices \| $ / shares	$ 2.88
Warrant Seven [Member]
Warrants Outstanding and Exercisable (Shares)	62,500
Exercise Prices \| $ / shares	$ 5

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Fair Value Assumptions of Warrant Liability (Details)	Sep. 30, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Number of warrants \| shares	62,500	62,500
Fair value of warrants \| $	$ 7,519	$ 13,323
Stock Price [Member]
Warrant liability, measurement input	0.20	0.22
Risk Free Interest Rate [Member]
Warrant liability, measurement input	0.16	1.62
Expected Volatility [Member]
Warrant liability, measurement input	148	145
Expected Life in Years [Member]
Warrant liability, measurement input, expected life (years)	3 years 6 months 3 days	4 years 3 months 4 days
Expected Dividend Yield [Member]
Warrant liability, measurement input	0	0

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Share-based Compensation, Stock Options, Activity (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Equity [Abstract]
Shares Outstanding, Beginning Balance \| shares	2,962,500
Shares, Granted \| shares	1,790,000
Shares, Forfeitures \| shares	(833,333)
Shares, Expirations \| shares
Shares, Exercised \| shares
Shares Outstanding, Ending Balance \| shares	3,919,167
Shares Exercisable, Ending Balance \| shares	2,327,500
Weighted Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 2.94
Weighted Average Exercise Price, Granted \| $ / shares	0.9
Weighted Average Exercise Price, Forfeitures \| $ / shares
Weighted Average Exercise Price, Expirations \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price Outstanding, Ending Balance \| $ / shares	1.69
Weighted Average Exercise Price Exercisable, Ending Balance \| $ / shares	$ 2.23
Weighted Average Remaining Contractual Term (Years) Outstanding, Beginning Balance	3 years 7 months 21 days
Weighted Average Remaining Contractual Term (Years), Granted	9 years 8 months 16 days
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	6 years 4 days
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	3 years 7 months 28 days

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Exercise Price of Options Outstanding and Exercisable (Details) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Options Outstanding (Shares)	3,919,167	2,962,500
Options Exercisable (Shares)	2,327,500
Exercise Price One [Member]
Options Outstanding (Shares)	250,000
Options Exercisable (Shares)	21,870
Exercise Prices	$ 0.25
Exercise Price Two [Member]
Options Outstanding (Shares)	30,000
Options Exercisable (Shares)	30,000
Exercise Prices	$ 0.32
Exercise Price Three [Member]
Options Outstanding (Shares)	250,000
Options Exercisable (Shares)	93,750
Exercise Prices	$ 0.39
Exercise Price Four [Member]
Options Outstanding (Shares)	10,000
Options Exercisable (Shares)	10,000
Exercise Prices	$ 0.41
Exercise Price Five [Member]
Options Outstanding (Shares)	100,000
Options Exercisable (Shares)	50,000
Exercise Prices	$ 0.54
Exercise Price Six [Member]
Options Outstanding (Shares)	1,500,000
Options Exercisable (Shares)	145,833
Exercise Prices	$ 1
Exercise Price Seven [Member]
Options Outstanding (Shares)	625,000
Options Exercisable (Shares)	625,000
Exercise Prices	$ 2
Exercise Price Eight [Member]
Options Outstanding (Shares)	62,500
Options Exercisable (Shares)	62,500
Exercise Prices	$ 2.30
Exercise Price Nine [Member]
Options Outstanding (Shares)	675,000
Options Exercisable (Shares)	675,000
Exercise Prices	$ 2.50
Exercise Price Ten [Member]
Options Outstanding (Shares)	416,667
Options Exercisable (Shares)	416,667
Exercise Prices	$ 4.40

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	9 Months Ended
Related Party Transactions (Details Narrative) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Ceatus Media Group, LLC [Member]
Consulting expenses	$ 45,500	$ 88,500
DWT Evans LLC [Member]
Building rent	16,114	15,648
Former CEO [Member] \| Karen Favish [Member]
Officers compensation	50,313	113,583
Chief Accounting Officer [Member] \| Kristine Townsend [Member]
Officers compensation	$ 45,000	$ 37,147
Dr. David Evans [Member]
Royalty percentage on sales	3.00%

Segment Reporting (Details Narr

Segment Reporting (Details Narrative)	9 Months Ended
Segment Reporting (Details Narrative)	Sep. 30, 2020Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Reporting - Schedule of

Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue	$ 253,188	$ 161,162	$ 1,689,820	$ 664,669
Cost of goods sold	114,113	70,999	867,800	261,547
Gross profit	139,075	90,163	822,020	403,122
Operating expenses	2,290,745	2,502,651	6,018,137	6,813,032
Loss from operations	(2,151,670)	(2,412,488)	(5,196,117)	(6,409,910)
Cash	9,795,441		9,795,441		$ 11,115,502
Inventories	1,284,173		1,284,173		310,941
Other	254,471		254,471		441,275
Total current assets	11,334,084		11,334,084		11,867,718
Right-of-use asset, net	457,677		457,677		572,714
Property and equipment, net	305,600		305,600		374,638
Intangible assets, net	50,000		50,000		50,000
Other	11,751		11,751		11,751
Total assets	12,159,112		12,159,112		12,876,821
Corporate [Member]
Revenue		35,000	6,100	9,800
Cost of goods sold		1,422	2,477	3,981
Gross profit		2,078	3,623	5,819
Operating expenses	1,202,402	1,235,389	2,655,107	3,195,227
Loss from operations	(1,202,402)	(1,233,311)	(2,651,484)	(3,189,408)
Cash	9,795,441		9,795,441		11,115,502
Inventories					5,003
Other	1,600		1,600		7,399
Total current assets	9,797,041		9,797,041		11,127,904
Right-of-use asset, net
Property and equipment, net					70,542
Intangible assets, net
Other
Total assets	9,797,041		9,797,041		11,198,446
Medical Foods and Nutraceuticals [Member]
Revenue	142,556	112,957	1,446,584	317,338
Cost of goods sold	68,956	41,655	764,246	120,608
Gross profit	73,600	71,302	682,338	196,730
Operating expenses	1,081,897	1,124,462	3,146,514	3,127,782
Loss from operations	(1,008,296)	(1,053,160)	(2,464,176)	(2,931,052)
Cash
Inventories	922,256		922,256		126,708
Other	150,659		150,659		219,223
Total current assets	1,072,915		1,072,915		345,931
Right-of-use asset, net	408,686		408,686		509,464
Property and equipment, net	146,163		146,163		148,514
Intangible assets, net	50,000		50,000		50,000
Other	11,751		11,751		11,751
Total assets	1,689,515		1,689,515		1,065,660
Medical Devices [Member]
Revenue	110,632	44,705	237,136	337,531
Cost of goods sold	45,157	27,922	101,077	136,958
Gross profit	65,475	16,783	136,059	200,573
Operating expenses	6,446	142,800	216,516	490,023
Loss from operations	59,028	$ (126,017)	(80,457)	$ (289,450)
Cash
Inventories	361,917		361,917		179,230
Other	102,211		102,211		214,653
Total current assets	464,128		464,128		393,883
Right-of-use asset, net	48,991		48,991		63,250
Property and equipment, net	159,437		159,437		155,582
Intangible assets, net
Other
Total assets	$ 672,555		$ 672,555		$ 612,715